ClinicalTrials.gg
CompletedNCT04599465Updated Aug 3, 2023Results posted

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 41 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-08-03.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
19th of 23
69 · median 120
Started
2021
with 2 others
Phase 3
19 of 23
none open now
Registered
14th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 19th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 14th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function mutation (F/MF genotypes), with abnormal glucose metabolism.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Heterozygous for F508del and an MF mutation (F/MF genotypes)
  • (FEV1) value ≥ 30% of predicted mean for age, sex, and height
  • Abnormal glucose tolerance determined by an OGTT as either:

    • Impaired glucose tolerance (IGT) defined as 2 hour post OGTT blood glucose level ≥140 to \<200 mg/dL (≥7.77 to \<11.10 mmol/L) and fasting blood glucose level \<126 mg/dL (\<7.00 mmol/L)
    • CF-related diabetes (CFRD) defined as either fasting hyperglycemia (blood glucose level ≥126 mg/dL [≥7.00 mmol/L] after an 8-hour fast) or 2-hour post OGTT blood glucose level ≥200 mg/dL (≥11.10 mmol/L)

Key Exclusion Criteria:

  • liver cirrhosis with or without portal hypertension
  • Solid organ or hematological transplantation
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Type 1 or Type 2 diabetes
  • Duration of CFRD ≥5 years

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Participants received ELX 200 mg /TEZ 100 mg /IVA 150 mg in the morning and IVA 150 mg in the evening.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed dose combination (FDC) tablets for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablets for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48

    Baseline 2-hour post-OGTT blood glucose level was defined as the average of valid pre-dose measurements at screening and Day 1. OGTT results were considered valid only when the participant was fasting for at least 8 hours.

    Time frame: Baseline, Week 36 and 48

Secondary outcomes

  1. Percentage of Participants With Improvement in Dysglycemia Categorization at Week 48

    Baseline dysglycemia category was defined as the most recent non-missing measurement before the first dose of study drug in the treatment period. Improvement in dysglycemia is a change from cystic fibrosis-related diabetes (CFRD) at baseline to impaired glucose tolerance (IGT)/normal glucose tolerance (NGT) at Week 48 OR change from IGT at baseline to NGT at Week 48. CFRD: 2-hour post-OGTT blood glucose level ≥200 mg/dL or fasting blood glucose level ≥126 mg/dL; IGT: 2-hour post-OGTT blood glucose level ≥140 to \<200 mg/dL and fasting blood glucose level \<126 mg/dL; NGT: 2 hour post-OGTT blood glucose level \<140 mg/dL and fasting blood glucose level \<126 mg/dL.

    Time frame: Baseline, Week 48

  2. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 52

07

Results

Posted Aug 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneELX/TEZ/IVA
Started69
Completed66
Not completed3
Withdrew: Physician decision1
Withdrew: Withdrawal of consent (not due to ae)2

Outcome measures

PrimaryChange From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48

Baseline 2-hour post-OGTT blood glucose level was defined as the average of valid pre-dose measurements at screening and Day 1. OGTT results were considered valid only when the participant was fasting for at least 8 hours.

Time frame:
Baseline, Week 36 and 48
Reported as:
Least squares mean · milligrams per deciliter (mg/dl)
Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48
milligrams per deciliter (mg/dl)ELX/TEZ/IVA
Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48-35.0 (-49.2 to -20.7)
SecondaryPercentage of Participants With Improvement in Dysglycemia Categorization at Week 48

Baseline dysglycemia category was defined as the most recent non-missing measurement before the first dose of study drug in the treatment period. Improvement in dysglycemia is a change from cystic fibrosis-related diabetes (CFRD) at baseline to impaired glucose tolerance (IGT)/normal glucose tolerance (NGT) at Week 48 OR change from IGT at baseline to NGT at Week 48. CFRD: 2-hour post-OGTT blood glucose level ≥200 mg/dL or fasting blood glucose level ≥126 mg/dL; IGT: 2-hour post-OGTT blood glucose level ≥140 to \<200 mg/dL and fasting blood glucose level \<126 mg/dL; NGT: 2 hour post-OGTT blood glucose level \<140 mg/dL and fasting blood glucose level \<126 mg/dL.

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in Dysglycemia Categorization at Week 48
percentage of participantsELX/TEZ/IVA
Percentage of Participants With Improvement in Dysglycemia Categorization at Week 4837.7 (24.8 to 52.1)
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 52
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsELX/TEZ/IVA
Participants with TEAEs67
Participants with SAEs6

Adverse events

Collected over Day 1 up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ELX/TEZ/IVA0/69 (0%)6/69 (8.7%)62/69 (89.9%)
Most frequent serious events
Most frequent serious events
EventELX/TEZ/IVA
GastritisGastrointestinal disorders1/69
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/69
InfluenzaInfections and infestations1/69
SinusitisInfections and infestations1/69
Clavicle fractureInjury, poisoning and procedural complications1/69
HeadacheNervous system disorders1/69
Heavy menstrual bleedingReproductive system and breast disorders1/69
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders1/69
Most frequent other events
Showing 10 of 28
Most frequent other events
EventELX/TEZ/IVA
COVID-19Infections and infestations22/69
PyrexiaGeneral disorders16/69
HeadacheNervous system disorders16/69
NasopharyngitisInfections and infestations15/69
DiarrhoeaGastrointestinal disorders13/69
Sputum increasedRespiratory, thoracic and mediastinal disorders12/69
CoughRespiratory, thoracic and mediastinal disorders11/69
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations10/69
Abdominal painGastrointestinal disorders9/69
Abdominal pain upperGastrointestinal disorders8/69

Baseline characteristics

All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.

Age, Customized
Age, Customized(Participants)ELX/TEZ/IVA
Less than (<)18 years19
More than or equal to (≥)18 years50
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Female31
Male38
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Hispanic or Latino8
Not Hispanic or Latino41
Not collected per local regulations20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
White48
Black or African American0
Asian0
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
Other1
Not collected per local regulations20
2-hour Post-OGTT Blood Glucose Levels
2-hour Post-OGTT Blood Glucose Levels(milligrams per deciliter (mg/dl))ELX/TEZ/IVA
Mean217.6 ± 73.1
08

Study locations

41 sites
  • Royal Adelaide Hospital
    Adelaide, Australia
  • The Prince Charles Hospital
    Chermside, Australia
  • Alfred Hospital
    Melbourne, Australia
  • Telethon Kids Institute
    Nedlands, Australia
  • The Royal Children's Hospital
    Parkville, VIC, Australia
  • Sydney Children's Hospital
    Randwick, Australia
  • Mater Adult Hospital
    South Brisbane, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • Westmead Hospital
    Westmead, Australia
  • Cliniques Universitaires de Bruxelles Hopital Erasme
    Brussels, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • Klinika Nemoci Plicnich a Tuberkulozy
    Brno, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, Czechia
  • Centre Hospitalier Intercommunal Creteil
    Créteil, France
  • CHRU de Lille - Hopital Albert Calmette
    Lille, France
  • CHU Marseille - Hopital Nord
    Marseille, France
  • Hopital Arnaud de Villeneuve
    Montpellier Cedex 5, France
  • Centre Hospitalier Universitaire De Nantes - G. R. Laennec
    Nantes, France
  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur
    Nice, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, France
  • CHU de Rouen - Hopital Charles Nicolle
    Rouen Cedex, Seine Maritime, France
  • Hopitaux Universitaires de Strasbourg
    Strasbourg, France
  • Hopital Foch (Suresnes), Hopital Foch, Adultes
    Suresnes, France
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
    Ancona, Italy
  • IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico
    Genova, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Italy
  • Azienda Ospedaliero Universitaria Federico II Napoli
    Naples, Italy
  • Azienda Ospedaliera di Verona - Ospedale Civile Maggiore
    Verona, Italy
  • Academisch Medisch Centrum (Academic Medical Centre)
    Amsterdam, Netherlands
  • HagaZiekenhuis van den Haag
    Den Haag, Netherlands
  • University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis
    Heidelberglaan, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • Hospital Saint Joan de Deu
    Barcelona, Spain
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Universitari Vall d´Hebron Servicio de Broncoscopia
    Barcelona, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • Hospital Virgen de la Arrixaca
    Murcia, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jul 2022, 17 months.

Results were first posted in Aug 2023, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 17 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Oct 22, 2020
StartActual
Jan 15, 2021
Primary completionActual
Jul 14, 2022
CompletionActual
Jul 14, 2022
Results first posted
Aug 3, 2023
Last update
Aug 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04599465
Responsible party
Sponsor
First posted
Oct 22, 2020
Start date
Jan 15, 2021
Primary completion
Jul 14, 2022
Completion
Jul 14, 2022
Results posted
Aug 3, 2023
Last update
Aug 3, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion